Prentiss Smith & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Prentiss Smith & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,200	Closed	-$69K	–	210
2018 Q3	$69K	Hold	3,200	–	–	0.04%	99
2018 Q2	$78K	Hold	3,200	–	–	0.05%	93
2018 Q1	$55K	Hold	3,200	–	–	0.03%	121
2017 Q4	$61K	Buy	3,200 +2,200	+220%	+$33.1K	0.03%	116
2017 Q3	$18K	Hold	1,000	–	–	0.01%	169
2017 Q2	$33K	Hold	1,000	–	–	0.02%	137
2017 Q1	$32K	Hold	1,000	–	–	0.02%	138
2016 Q4	$36K	Buy	+1,000	New	+$39.9K	0.02%	136
2013 Q3	–	Sell	-61,496	Closed	-$2.41M	–	262
2013 Q2	$2.41M	Buy	+61,496	New	+$2.39M	1.25%	23

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Prentiss Smith & Co's TEVA Position: Q4 2018 in Review

Prentiss Smith & Co sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 3,200 shares — an estimated $69K sold.

Prentiss Smith & Co first reported a position in TEVA in Q2 2013 and held it in 9 quarters. The position peaked at $2.41M in Q2 2013. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Prentiss Smith & Co reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Prentiss Smith & Co sold 3,200 Teva Pharmaceuticals shares in Q4 2018, an estimated $69K.
Prentiss Smith & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Prentiss Smith & Co's Teva Pharmaceuticals position peaked at $2.41M in Q2 2013.
552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Prentiss Smith & Co's 13F filing for Q4 2018, filed 15 Jan 2019.